Clinicopathological profile of endometrial carcinoma in postmenopausal women: A hospital-based cross-sectional study.
DOI:
https://doi.org/10.51168/p84aka29Keywords:
Endometrial carcinoma, Postmenopausal women, Histopathology, FIGO staging, Clinicopathological profileAbstract
Background
Endometrial carcinoma is among the most common gynecological malignancies in postmenopausal women and requires early diagnosis for improved outcomes.
Objective: To evaluate the clinicopathological profile of endometrial carcinoma in postmenopausal women attending a tertiary care hospital.
Methods
This hospital-based cross-sectional study included 100 postmenopausal women with histopathologically confirmed endometrial carcinoma. Clinical features, histopathological findings, and FIGO stage were analyzed using SPSS version 26. The association between tumor grade and stage was assessed using the Chi-square test.
Results
The mean age was 61.4 ± 7.8 years, and 45% of patients belonged to the 50–60-year age group. Postmenopausal bleeding was the most common symptom (82%). Endometrioid carcinoma was the predominant subtype (78%), while 56% of patients presented in FIGO Stage I. Tumor grade showed a significant association with disease stage (χ²=28.6, p=0.001).
Conclusion
Endometrial carcinoma commonly presents with postmenopausal bleeding and is frequently diagnosed at an early stage. Histopathological grade is significantly associated with disease stage and prognosis.
Recommendation
Early evaluation of postmenopausal bleeding and prompt histopathological assessment should be encouraged to improve diagnosis and management.
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. https://doi.org/10.3322/caac.21590 PMid:31912902
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492 PMid:30207593
3. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer. Ann Oncol. 2016;27(1):16-41. https://doi.org/10.1093/annonc/mdv484 PMid:26634381
4. Goldstein SR. Modern evaluation of the endometrium. Obstet Gynecol. 2010;116(1):168-176. https://doi.org/10.1097/AOG.0b013e3181dfd557 PMid:20567184
5. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-17. https://doi.org/10.1016/0090-8258(83)90111-7 PMid:6822361
6. Kurman RJ, Ellenson LH, Ronnett BM. Blaustein's pathology of the female genital tract. 6th ed. New York: Springer; 2011.https://doi.org/10.1007/978-1-4419-0489-8
7. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk. Endocr Rev. 2002;23(6):593-613.
8. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73. https://doi.org/10.1038/nature12113 PMid:23636398
9. Mutter GL, Zaino RJ, Baak JP, Bentley RC, Robboy SJ. Benign endometrial hyperplasia sequence and carcinoma risk. J Clin Oncol. 2014;32(5):1-9.
10. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the endometrium. Int J Gynecol Obstet. 2009;105(2):103-104. https://doi.org/10.1016/j.ijgo.2009.02.012 https://doi.org/10.1016/j.ijgo.2009.02.009 PMid:19342051
11. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, et al. Type I and II endometrial cancers. J Clin Oncol. 2013;31(20):2607-2618. https://doi.org/10.1200/JCO.2012.48.2596 PMid:23733771 PMCid:PMC3699726
12. Sorosky JI. Endometrial cancer. Am J Obstet Gynecol. 2008;198(2):135-144. https://doi.org/10.1097/AOG.0b013e31817f2419 https://doi.org/10.1097/AOG.0b013e318162f690 PMid:18238985
13. Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(8):2002-2011. https://doi.org/10.1007/s10552-010-9612-8 PMid:20628804 PMCid:PMC2962676
14. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. Int J Gynecol Obstet. 2006;95(Suppl 1):S105-S143. https://doi.org/10.1016/S0020-7292(06)60031-3
15. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387(10023):1094-1108.https://doi.org/10.1016/S0140-6736(15)00130-0 PMid:26354523
16. Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, et al. Current recommendations for endometrial cancer. CA Cancer J Clin. 2019;69(4):258-279. https://doi.org/10.3322/caac.21561 PMid:3107486
17. Lu KH, Broaddus RR. Endometrial cancer. N Engl J Med. 2013;369(18):1703-1713.
18. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366(9484):491-505. https://doi.org/10.1016/S0140-6736(05)67063-8 PMid:16084259
19. Denschlag D, Ulrich U, Emons G. The diagnosis and treatment of endometrial cancer. Dtsch Arztebl Int. 2010;107(20):361-367.
20. Setiawan VW, Pike MC, Kolonel LN, Nomura AM, Goodman MT, Henderson BE. Racial/ethnic differences in endometrial cancer risk. Cancer. 2019;125(2):1-10.
21. Sorosky J. Endometrial cancer overview. Obstet Gynecol. 2012;120(2):383-397. https://doi.org/10.1097/AOG.0b013e3182605bf1 PMid:22825101
22. Timmermans A, Opmeer BC, Khan KS, Bachmann LM, Epstein E, Clark TJ, et al. Endometrial thickness measurement. Obstet Gynecol. 2010;116(1):160-167. https://doi.org/10.1097/AOG.0b013e3181e3e7e8 PMid:20567183
23. Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma. Mod Pathol. 2014;27(S1):S22-S36.
24. Prat J. FIGO staging for uterine corpus cancer. Int J Gynecol Pathol. 2015;34(1):1-6.
25. Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, et al. Molecular classification of endometrial carcinoma. Cancer. 2015;121(7):1-10.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dr. Bishal Datta, Dr. Prannoy Das, Dr. Bhabani Charan Das (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
